Inhibitory T cell receptor peptides and discovery methods
AssigneeJanux Therapeutics, Inc.
InventorsDavid Campbell, Ramesh Bhatt, Thomas Diraimondo
Life of this patent
Estimating the term…
Abstract
Disclosed herein are methods of inhibiting an interaction of a T cell receptor with a peptide-major histocompatibility complex comprising administering inhibitory peptides that bind to the T cell receptor without the aid of a major histocompatibility complex to inhibit the interaction, and methods of identifying the inhibitory peptides.
Claims6
A method of inhibiting an interaction of a T cell receptor (TCR) with a peptide-major histocompatibility (pMHC) complex, the method comprising administering to the TCR and the pMHC an inhibitory peptide that binds to the TCR without the aid of a MHC, thereby inhibiting the interaction of the TCR with the pMHC complex,
- wherein the TCR comprises a TCR alpha extracellular domain comprising a variable region of the alpha extracellular domain of the TCR and a TCR beta extracellular domain comprising a variable region of the beta extracellular domain of the TCR,
- wherein the TCR is a Mage-A3 TCR, and wherein the inhibitory peptide comprises an amino acid sequence according to any one of SEQ ID NOs:
- 11, 12, 15, 16, 17, 19, 22, 23, and 25.
A method of inhibiting an interaction of a T cell receptor (TCR) with a peptide-major histocompatibility (pMHC) complex, the method comprising administering to the TCR and the pMHC an inhibitory peptide that binds to the TCR without the aid of a MHC, thereby inhibiting the interaction of the TCR with the pMHC complex,
- wherein the TCR comprises a TCR alpha extracellular domain comprising a variable region of the alpha extracellular domain of the TCR and a TCR beta extracellular domain comprising a variable region of the beta extracellular domain of the TCR;
- and
- wherein the TCR is a gp100 TCR, and wherein the inhibitory peptide comprises an amino acid sequence according to any one of SEQ ID NOs:
- 61, 62, 63, 67, and 69.
A method of inhibiting an interaction of a T cell receptor (TCR) with a peptide-major histocompatibility (pMHC) complex, the method comprising administering to the TCR and the pMHC an inhibitory peptide that binds to the TCR without the aid of a MHC, thereby inhibiting the interaction of the TCR with the pMHC complex,
- wherein the TCR comprises a TCR alpha extracellular domain comprising a variable region of the alpha extracellular domain of the TCR and a TCR beta extracellular domain comprising a variable region of the beta extracellular domain of the TCR;
- and
- wherein the TCR is a HIV TCR, and wherein the inhibitory peptide comprises an amino acid sequence according to SEQ ID NO:
- 106.
Dependencies are inferred from the claim text.